Stock Events

Stock Events

BioVaxys Technology 

€0.03
0
-€0-9.52% Thursday 06:06

Statistics

Day High
0.03
Day Low
0.03
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-2.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5LB0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novavax
NVAX
Mkt Cap1.36B
Novavax is a competitor because it also focuses on developing vaccines for infectious diseases, similar to BioVaxys's focus on COVID-19 and cancer vaccines.
Moderna
MRNA
Mkt Cap10.61B
Moderna is a direct competitor in the mRNA vaccine space, particularly for COVID-19, competing with BioVaxys's vaccine development efforts.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech competes in the development of vaccines for infectious diseases and cancer, directly overlapping with BioVaxys's areas of focus.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, in collaboration with BioNTech, competes in the COVID-19 vaccine market, directly affecting BioVaxys's vaccine initiatives.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson competes in the vaccine market with its own COVID-19 vaccine, posing competition to BioVaxys's development efforts.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca competes in the COVID-19 vaccine space, which is a key area of development for BioVaxys.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes in the development of vaccines, including for infectious diseases, making it a competitor to BioVaxys.
Sanofi
SNY
Mkt Cap124.45B
Sanofi competes in the vaccine market, including efforts in developing COVID-19 vaccines, making it a competitor to BioVaxys.
Inovio Pharmaceuticals
INO
Mkt Cap124.89M
Inovio Pharmaceuticals competes in the development of DNA vaccines for infectious diseases and cancer, overlapping with BioVaxys's focus areas.

About

BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
Show more...
CEO
ISIN
CA09076M2004
WKN
000A41C58

Listings

CN
CA
BIOV.CN
F
DE
5LB0.F
OTC Link
US
BVAXF

0 Comments

Share your thoughts

FAQ

What is BioVaxys Technology stock price today?▼
The current price of 5LB0.F is €0.03 EUR — it has decreased by -9.52% in the past 24 hours. Watch BioVaxys Technology stock price performance more closely on the chart.
What is BioVaxys Technology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange BioVaxys Technology stocks are traded under the ticker 5LB0.F.
What is BioVaxys Technology revenue for the last year?▼
BioVaxys Technology revenue for the last year amounts to 0 EUR.
What is BioVaxys Technology net income for the last year?▼
5LB0.F net income for the last year is -2.62M EUR.
When did BioVaxys Technology complete a stock split?▼
The last stock split for BioVaxys Technology was on September 11, 2025 with a ratio of 1:10.